tbuckley/cabot-search huggingface dataset:
Context-Specific Roles for Erythroid Krüppel-Like Factor (EKLF) in Co-Ordinate High Level Expression of the Murine α- and β-Globin Genes.
Authors: Valerie M. Jansen, Shaji Ramachandran, Aurelie Desgardin, Jin He, Vishwas Parekh, Stephen M. Jane, John M. Cunningham
Journal: Blood (2006)
Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia
Authors: Brian M. Thomas, Scott H. Kaufmann, Jacqueline M Greer, Steven D. Gore, Keith W. Pratz, B. Douglas Smith, Karen Mackey, Sabine Loechner, Jo Ann Horowitz, Judith E. Karp
Journal: Blood (2011)
Notch Activation in Cord Blood Progenitors Induces a CD7+ Common NK/T Precursor Capable of NK Cell Commitment without Full Maturation and Differentiation of Lineage Committed Pre-T Lymphocytes with a Th1 Phenotype.
Authors: Veronika Bachanova, Valarie McCullar, Rosanna Wangen, Jeffrey S. Miller
Journal: Blood (2006)
Molecular Background of BCP-ALL Cases with an Early Switch to Monocytic Lineage
Authors: Karel Fier, Lucie Slámová, Alena Dobiáová, Júlia Starková, Eva Froňková, Markéta Aliová, Kamila Polgárová, Maria E Figueroa, Tomá Kalina, Jan Zuna, Jan Trka, Jan Starý, Ondřej Hruák, Ester Mejstříková
Journal: Blood (2014)
JAK2V617F Mutation Persists IN Blasts and Mature CELLS of Transformed- JAK2V617F-POSITIVE-MYELOPROLIFERATIVE Neoplasia: A European LEUKEMIA NET (ENL) STUDY
Authors: Ciro R Rinaldi, Paola Rinaldi, Adele Alagia, Marica Gemei, Luigi Del Vecchio, Bruno Martino, Giorgina Specchia, Anna Candoni, Luigi Gugliotta, Alessandro M. Vannucchi, Tiziano Barbui, Fabrizio Pane
Journal: Blood (2010)
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
Authors: Eleftherios P. Mamounas, Qing Liu, Soonmyung Paik, Frederick L. Baehner, Gong Tang, Jong-Hyeon Jeong, S. Rim Kim, Steven M. Butler, Farid Jamshidian, Diana B. Cherbavaz, Amy P. Sing, Steven Shak, Thomas B. Julian, Barry C. Lembersky, D. Lawrence Wickerham, Joseph P. Costantino, Norman Wolmark
Journal: JNCI Journal of the National Cancer Institute (2017)

Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node-negative, estrogen receptor (ER)–positive breast cancer. We evaluated the association between RS and LRR in node-positive, ER-positive patients treated with adjuvant chemotherapy plus tamoxifen in National Surgical Adjuvant Breast and Bowel Project B-28. Methods: B-28 compared doxorubicin/cyclophosphamide (AC X 4) with AC X 4 followed by paclitaxel X 4. Tamoxifen was given to patients age 50 years or older and those younger than age 50 years with ER-positive and/or progesterone receptor–positive tumors. Lumpectomy patients received breast radiotherapy. Mastectomy patients received no radiotherapy. The present study includes 1065 ER-positive, tamoxifen-treated patients with RS assessment. Cumulative incidence functions and subdistribution hazard regression models were used for LRR to account for competing risks including distant recurrence, second primary cancers, and death from other causes. Median follow-up was 11.2 years. All statistical tests were one-sided. Results: There were 80 LRRs (7.5%) as first events (68% local/32% regional). RS was low: 36.2%; intermediate: 34.2%; and high: 29.6%. RS was a statistically significant predictor of LRR in univariate analyses (10-year cumulative incidence of LRR = 3.3%, 7.2%, and 12.2% for low, intermediate, and high RS, respectively, P < .001). In multivariable regression analysis, RS remained an independent predictor of LRR (hazard ratio [HR] = 2.59, 95% confidence interval [CI] = 1.28 to 5.26, for a 50-point difference, P = .008) along with pathologic nodal status (HR = 1.91, 95% CI = 1.20 to 3.03, for four or more vs one to three positive nodes, P = .006) and tumor size (HR = 1.28, 95% CI = 1.05 to 1.55, for a 1 cm difference, P = .02). Conclusions: RS statistically significantly predicts risk of LRR in node-positive, ER-positive breast cancer patients after adjuvant chemotherapy plus tamoxifen. These findings can help in the selection of appropriate candidates for comprehensive radiotherapy.
Oncogene Cooperativity Analysis Reveals a Novel Set of Genes That Regulate the In Vivo Growth and Survival of Leukemia Stem Cells
Authors: John M Ashton, Marlene Balys, Sarah Neering, Glenn Cowley, David E. Root, Peter G. Miller, Benjamin Ebert, Helene McMurray, Duane C Hassane, Hartmut Land, Craig T. Jordan
Journal: Blood (2011)
A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.
Authors: Edmund A Rossi, Chien-Hsing Chang, Thomas M Cardillo, Diane L Nordstrom, David M. Goldenberg
Journal: Blood (2008)
Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy
Authors: Guifa Xi, Yuping Derek Li, Gordan Grahovac, Veena Rajaram, Nitin Wadhwani, Tatiana Pundy, Barbara Mania-Farnell, Charles David James, Tadanori Tomita
Journal: Molecular Cancer (2017)

Pilocytic astrocytomas (PAs) are the most common pediatric central nervous system neoplasms. In the majority of cases these tumors are benign and receive favorable prognosis following gross total surgical resection. In patients with progressive or symptomatic tumors, aggressive surgical resection is generally not feasible, thus radiation or chemotherapy are accepted initial or adjuvant interventions. Due to serious long-lasting side-effects, radiation is limited in young children; therefore, chemotherapy is widely practiced as an adjuvant treatment for these patients. However, chemotherapy can promote the emergence of multidrug resistant tumor cells that are more malignant than those of the original tumor. CD133, a putative stem cell marker in normal tissue and malignant brain tumors, enhances multidrug resistant gene 1 (MDR1) expression following chemotherapy in adult malignant glioblastomas. This study examines the relationship between CD133 and MDR1 in pediatric PAs exposed to chemotherapy, with the goal of identifying therapeutic targets that manifest as a result of chemotherapy.Slides were obtained for 15 recurrent PAs, seven of which had received chemotherapy prior to surgical treatment for the recurrent tumor. These samples, as well as primary tumor tissue slides from the same patients were used to investigate CD133 and MDR1 expression via immunofluorescence. Archived frozen tissue samples from the same patients were used to examine CD133, MDR1 and PI3K-Akt-NF-κB signaling mediators, via western blot. Two drug resistant pediatric PA cell lines Res186 and Res199 were also used to evaluate the role of CD133 on cell response to cytotoxic therapy.CD133 and MDR1 were co-expressed and their expression was elevated in recurrent PAs from patients that had received chemotherapy, compared to patients that had not received chemotherapy. PI3K-Akt-NF-κB signaling mediator expression was also elevated in recurrent, chemotherapy-treated PA. Suppressing CD133 expression with siCD133 decreased levels of PI3K-Akt-NF-κB signaling mediators and MDR1, while increasing cell chemosensitivity, as indicated by quantification of apoptotic cells following chemotherapy.CD133 contributes to multidrug resistance by regulating MDR1 levels via the PI3K-Akt-NF-κB signal pathway not only in adult glioblastomas, but also in pediatric PAs. Targeting CD133, adjuvant to conventional chemotherapy may improve outcomes for children with recurrent PA.
High Incidence but Low Morbitiy of Early Cytomegalovirus (CMV) Infections Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation with Alemtuzumab and Ganciclovir Prophylaxis.
Authors: Renu Lamba, George Carrum, Robert Krance, Helen Heslop, Malcolm Brenner, Uday Popat
Journal: Blood (2004)
Detection of cis-mutations in the activation loop of the <i>KIT</i> gene in sunitinib-resistant gastrointestinal stromal tumors
Authors: T. Nishida, T. Takahashi, K. Nakajima, A. Nishitani, S. Hirota
Journal: Journal of Clinical Oncology (2008)

10521 Background: Although sunitinib malate has shown significant clinical effect on imatinib-resistant gastrointestinal stromal tumors with acceptable tolerability and improved prognosis for the patients, the mechanism of resistance to the drug is still under investigation. Methods: We analyzed eight pts (7 males, 1 female, median age 59) of 17 pts with imatinib-resistant gastrointestinal stromal tumors treated by sunitinib. Sunitinib was orally administered once a day at a starting dose of 37.5 mg/day, 50 or 75 with 4 wks on and 2 weeks off. Results: All imatinib- as well as sunitinib-resistant lesions showed viable tumor cells strongly re-expressing KIT protein. All pre-imatinib samples had heterogenous KIT mutations either in exon 9 (n=1) or exon 11 (n=7), and seven imatinib-resistant tumors carried secondary mutations either in the ATP-binding domain (n=4) or in the activation loop (n=3) in the same allele as the primary mutation. Pts with resistant tumors carrying secondary mutations purely in the ATP-binding domain obtained clinical benefits from sunitinib, whereas most pts carrying activation loop mutations showed early resistance to the drug. The tumor with mutations in exon 11 and 13 of the KIT gene and showing partial response to sunitinib harbored a third mutation in the activation loop after sunitinib resistance. All additional secondary and tertiary mutations were located in the same allele as the primary mutation (cis-mutation). Conclusions: These findings indicate that imatinib- as well as sunitinib-resistant lesions re-express KIT protein and that additional cis-mutation in the activation loop may be a major cause of sunitinib resistance in gastrointestinal stromal tumor. No significant financial relationships to disclose.
Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML
Authors: Armin Leitner, Susanne Saussele, Claudia Haferlach, Brigitte Schlegelberger, Gudrun Göhring, Susanne Jung-Munkwitz, Ulrike Proetel, Michael Lauseker, Markus Pfirrmann, Jörg Hasford, Andreas Hochhaus, Rüdiger Hehlmann
Journal: Blood (2010)
MicroRNA Expression in Childhood Acute Lymphoblastic Leukemia (ALL)
Authors: Yung-Li Yang, Sung-Liang Yu, Hsuan-Yu Chen, Pan-Chyr Yang, Jiann-Shiuh Chen, Dong-Tsamn Lin, Shu-Rung Lin, Shiann-Tarng Jou, Ching-Tzu Yen, Kai-Hsin Lin, Chung-Yi Hu, Sheng-Kai Chang, Rong-Jing Chiou, Meng-Yao Lu, Hsiu-Hao Chang, Shu-Wha Lin
Journal: Blood (2008)
Gentuzumab-Ozogamicin, Citosine Arabinoside, G-CSF Combination (G-AraMy) in the Treatment of Secondary Acute Myeloid Leukemia in Elderly Patients.
Authors: Livio Pagano, Luana Fianchi, Franco Leoni, Sergio Storti, Maria Teresa Voso, Caterina Giovanna Valentini, Alessandra Scardocci, Morena Caira, Alberto Bosi, Giupeppe Leone
Journal: Blood (2007)
Evaluating the Safety of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Breast Cancer, Lung Cancer, and Hematologic Malignancies: A Meta-Analysis of Randomized, Controlled Trials.
Authors: J. Glaspy, D. Henry, J. Vansteenkiste, H. Ludwig, T. Lillie, D. Tomita, J. Crawford
Journal: Blood (2007)
The Severe Chronic Neutropenia International Registry - 10 Years of Follow-Up.
Authors: David C. Dale, Audrey Anna Bolyard, Beate Schwinzer, Gusal Pracht, Mary Ann Bonilla, Laurence Boxer, Melvin Freedman, Jean Donadieu, George Kannourakis, Blanche P. Alter, Bonnie Cham, Jerry Winkelstein, Sally E. Kinsey, Carol Fier, Connie Zeidler, Karl Welte
Journal: Blood (2004)
Bolstering Community Cooperation in Ebola Resurgence Protocols: Combining Field Blood Draw and Point-of-Care Diagnosis
Authors: Mosoka P. Fallah, Laura A. Skrip, Philomena Raftery, Miata Kullie, Watta Borbor, A. Scott Laney, David J. Blackley, Athalia Christie, Emily Kainne Dokubo, Terrence Q. Lo, Stewart Coulter, April Baller, Benjamin T. Vonhm, Philip Bemah, Sowillie Lomax, Adolphus Yeiah, Yatta Wapoe-Sackie, Jennifer Mann, Peter Clement, Gloria Davies-Wayne, Esther Hamblion, Caitlin Wolfe, Desmond Williams, Alex Gasasira, Francis Kateh, Tolbert G. Nyenswah, Alison P. Galvani
Journal: PLoS Medicine (2017)

BackgroundOn May 9, 2015, the World Health Organization (WHO) declared Liberia to be free of known Ebola virus transmission following a 14-month epidemic that resulted in nearly 4,800 deaths within Liberia alone [1].Since this declaration, three Ebola resurgences have occurred in Liberia (June 2015, November 2015, March 2016), and others have occurred in Sierra Leone (January 2016) and Guinea (March 2016).Whereas outbreaks of Ebola have been characterized by Summary Points• Community resistance arising from fear, stigma, and lingering trauma following the devastating Ebola outbreak has posed challenges for surveillance in Liberia.• During localized resurgences of Ebola since May 2015, a protocol of field blood draw by trained personnel combined with PCR-based GeneXpert diagnosis was developed as an option for individuals suspected of having Ebola who refused admission to Ebola treatment units (ETUs), where diagnosis is typically conducted.• This new protocol bolstered community cooperation, accelerated diagnosis, and facilitated rapid isolation of patients with Ebola, which is in turn fundamental to curtailing household transmission and improving prognosis.• Potential limitations of the protocol include the requirement of deployable human resources with necessary laboratory expertise and proximity to diagnostic facilities.A further consideration is the trade-off between the occupational risk of conducting blood draw in the field and the transmission risk to individuals suspected of having Ebola awaiting results in the ETU.
Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual
Authors: William M. Lydiatt, Snehal G. Patel, Brian O'Sullivan, Margaret S. Brandwein, John A. Ridge, Jocelyn C. Migliacci, Ashley M. Loomis, Jatin P. Shah
Journal: CA A Cancer Journal for Clinicians (2017)

Answer questions and earn CME/CNE The recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section, introduces significant modifications from the prior seventh edition. This article details several of the most significant modifications, and the rationale for the revisions, to alert the reader to evolution of the field. The most significant update creates a separate staging algorithm for high-risk human papillomavirus-associated cancer of the oropharynx, distinguishing it from oropharyngeal cancer with other causes. Other modifications include: the reorganizing of skin cancer (other than melanoma and Merkel cell carcinoma) from a general chapter for the entire body to a head and neck-specific cutaneous malignancies chapter; division of cancer of the pharynx into 3 separate chapters; changes to the tumor (T) categories for oral cavity, skin, and nasopharynx; and the addition of extranodal cancer extension to lymph node category (N) in all but the viral-related cancers and mucosal melanoma. The Head and Neck Task Force worked with colleagues around the world to derive a staging system that reflects ongoing changes in head and neck oncology; it remains user friendly and consistent with the traditional tumor, lymph node, metastasis (TNM) staging paradigm. CA Cancer J Clin 2017;67:122–137. © 2017 American Cancer Society.
Processed Food—An Experiment That Failed
Authors: Robert H. Lustig
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Evaluation of clinical cardiotoxicity of nonpegylated liposomal doxorubicin in the treatment of patients with metastatic breast cancer (MBC) who had received prior adjuvant anthracyclines
Authors: C. Serrano, E. Muñoz, I. Braña, P. Martínez, C. Saura, I. R. Quispe, F. Atzori, P. Gómez, E. Calvo-Aller, J. A. Cortes
Journal: Journal of Clinical Oncology (2008)

1132 Background: The cumulative use of anthracyclines in MBC is often limited by cardiomyopathy and the risk of developing congestive heart failure (CHF). Nonpegylated liposomal doxorubicin (M) was designed to reduce the risk of cardiotoxicity associated with doxorubicin while preserving its antitumor efficacy. This analysis ascertains, on a daily basis, the cardiotoxicity of M in pts with MBC previously treated with anthracyclines. Methods: To participate in this retrospective analysis, pts were required to have an ECOG PS 0–2, an adequate organ function and a basal left ventricular ejection fraction (LVEF) > 50%, which was repeated at least once while on therapy with M. A cardiac event was defined as TYPE A in case of signs and/or symptoms consistent with CHF plus grade 3/4 LVEF decline. TYPE B cardiac events implied asymptomatic LVEF decline, defined as an absolute drop ≥10% resulting in a final LVEF < 50%, any absolute drop >20%, or LVEF < 40%. A maximum dose of 600 mg/m2 of M was permitted. Previous liposomal anthracyclines were not allowed. Results: From 05/04 to 08/07, 41 consecutive women who received prior adjuvant anthracyclines (36 doxorubicin, 5 epirubicin) were treated with M. Median age: 54 ys (range 25–77 ys). Median previous doxorubicin dose was 360 mg/m2 (range 180–940). Nine HER2+ MBC pts also received prior trastuzumab (T). 28 pts (68%) received M 60 mg/m2 with cyclophosphamide 600 mg/m2, 8 pts (10%) with taxanes (M 50 or 60 mg/m2) and 5 pts were treated with M mono (60 or 75 mg/m2); 6 pts received also T. Median number of cycles was 6 (range, 2–8), resulting in a median cumulative dose of 295 mg/m2 (range 100–600). Median LVEF at baseline for the whole group was 57.4% (95%CI 56 to 60%), declining to 51,4% (95%CI 49 to 51%) after administration of 2nd-line of anthracyclines with M. No TYPE A cardiac events were observed and 10 pts (24%) experienced an asymptomatic type B cardiac event. No cardiac events were observed in pts treated with M and T. Conclusions: Administration of anthracyclines-based therapy with M in MBC patients after prior adjuvant anthracyclines seems to be safe. In this setting, the absence of relevant cardiac toxicity with M merits further investigation in prospective trials. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Cephalon, Roche
The Cell Expression of PML-RARa at Diagnosis Has a Marginal Correlation with Prognosis in Patients with Acute Promyelocytic Leukemia (APL).
Authors: Carina Fernández, Carmen Chillón, Lorena Blázquez, F. Ramos, J. Fernández-Calvo, C. Rayón, A. Balanzategui, P. Martín-jiménez, M. Alcoceba, M. E. Sarasquete, A. Armellini, R. García-Sanz, M. González, J.F. San Miguel
Journal: Blood (2004)
Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD,
Authors: Felicitas Thol, Frederik Damm, Katharina Wagner, Katarina Reinhardt, Jan-Henning Klusmann, Nils von Neuhoff, Brigitte Schlegelberger, Dirk Reinhardt, Jürgen Krauter, Arnold Ganser, Michael Heuser
Journal: Blood (2011)
Adding wearable technology to a behavioral program resulted in less weight loss than adding Web-based self-monitoring
Authors: Warren G. Thompson
Journal: Annals of Internal Medicine (2017)

Source Citation Jakicic JM, Davis KK, Rogers RJ, et al. Effect of wearable technology combined with a lifestyle intervention on long-term weight loss: the IDEA randomized clinical trial. JAMA. 2016;316:1161-71. 27654602
Hyaluronic acid modification of RNase A and its intracellular delivery using lipid-like nanoparticles
Authors: Xiaoying Wang, Yamin Li, Quanshun Li, Caleb I. Neufeld, Dimitra Pouli, Shuo Sun, Liu Yang, Pu Deng, Ming Wang, Irene Georgakoudi, Shunqing Tang, Qiaobing Xu
Journal: Journal of Controlled Release (2017)
Abstract 15974: Salutary Effects of a Novel Implantable Counterpulsation Assist Device on Left Ventricular Mechanoenergetics in a Porcine Model of Acute Heart Failure
Authors: Konstantinos Malliaras, Yannis Nanas, Chris Kontogiannis, Dionysios Aravantinos, Chris Kapelios, Sotirios Marinakis, Smaragda Sarchosi, Stella Vakrou, Despina Perrea, John Nanas
Journal: Circulation (2016)

Introduction: We have developed the Pressure Unloading Left Ventricular Assist Device (PULVAD), a novel implantable counterpulsation LVAD, designed to provide LV pressure unloading with augmentation of LV performance and retention of pulsatility. We assessed the effects of PULVAD on hemodynamics, LV mechanoenergetics and myocardial perfusion in a porcine model of acute heart failure (aHF).

Methods: PULVAD comprises a pneumatically-driven pumping chamber implanted in the thoracic cavity and connected to the ascending aorta. PULVAD is ECG-synchronized and operates under the counterpulsation principle: deflation of the device air chamber just prior and during systole draws blood from the aorta into the device blood chamber, while inflation of the device air chamber during diastole ejects blood from the device blood chamber into the aorta. Seven farm pigs were instrumented with Millar catheter, sonomicrometry crystals and a Doppler flow probe placed around the left anterior descending artery (LAD). Pigs underwent PULVAD implantation and induction of aHF by LAD ligation for 60 minutes, followed by reperfusion. PULVAD was driven by a standard intra-aortic balloon pump console. Hemodynamics, indices of LV mechanoenergetics and LAD blood flow were measured without and after brief (<60 secs) PULVAD support during reperfusion.

Results: PULVAD support induced a profound reduction of LV afterload (systolic aortic pressure decreased by 19.2 mmHg and end-diastolic aortic pressure decreased by 22.3 mmHg). PULVAD support improved the mechanical performance of the failing LV (increased ejection fraction by 4.2%, cardiac output by 0.3 l/min and maximum elastance by 0.74 mmHg/ml). The PULVAD concurrently decreased LV energy consumption (stroke work decreased by 16% and pressure volume area decreased by 25%) and optimized LV energetic performance (improved the ratio of stroke work to pressure volume area from 52.8% to 59.0%). PULVAD support increased mean coronary blood flow by 34%, through dramatic augmentation (66%) of diastolic blood flow.

Conclusions: The PULVAD unloads the failing LV, optimizes LV mechanoenergetics and augments coronary blood flow. These salutary effects of short-term PULVAD support provide the foundation for long-term testing.